Phase 1 study of TZLS-501 in healthy volunteers
Latest Information Update: 29 Dec 2022
Price :
$35 *
At a glance
- Drugs TZLS 501 (Primary)
- Indications Inflammation; Interstitial lung diseases
- Focus Adverse reactions
- 27 Dec 2022 According to a Tiziana Life Sciences media release, the company has filed an IND for this study.
- 28 Sep 2021 New trial record